Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In OvaScience, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at OvaScience, Inc. (“OvaScience” or the “Company”) (NASDAQ: OVAS).
The investigation focuses on whether the Company and its executives violated federal securities laws with respect to its disclosures concerning business, operational, and compliance policies.
Specifically, the investigation focuses on whether OvaScience misrepresented to the FDA and the investing public that its AUGMENT technology qualified for 361 HCT/P designation and therefore did not need FDA licensure in order to be tested and marketed.
On September 10, 2013, the Company announced that it would suspend enrollment of AUGMENT in the U.S. after receiving an “untitled” letter from the FDA questioning the designation of AUGMENT as 361 HCT/P.
Following this news, OvaScience’s stock declined by $3.32 or over 23%.
If you invested in OvaScience stock or options between February 25, 2013 and September 10, 2013 and would like to discuss your legal rights, you can contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com or firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding OvaScience’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.